Milestone Pharmaceuticals Inc. (MIST): R&D Expense
$18.11M
Year ended 2025-12-31
$16.22M
Trailing 12 months to 2026-06-30
-23.1%
3-year compound annual growth
-12.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.11M | +26.1% | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | $14.36M | -53.8% | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | $31.05M | -22.0% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $39.83M | +3.0% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $38.67M | +12.1% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $34.49M | -17.9% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $41.98M | +149.2% | 2021-03-29, From 2019-01-01 |
| 2018-12-31 | $16.85M | n/a | 2020-10-23, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $18.11M | +26.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $65.58M | +3.0% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Rezolute, Inc. (RZLT) | 2026-06-30 | $53.80M | -12.6% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $39.05M | +1.6% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $69.88M | +19.4% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $48.94M | +181.8% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
Compare MIST, KRRO, RFL, RZLT side by side · Screen every company in Pharmaceutical Preparations ↗